A Study to Learn About the Study Medicine Called PF-08046032 in People With Advanced Cancers

Inclusion Criteria

• •1. Histological or cytological diagnosis of metastatic or unresectable malignancy:
• •* Part A1: Participants with lymphomas (cHL, PTCL, large B-cell lymphoma) who have progressed on/after standard therapies
• •* Part A2: Participants with solid tumors (NSCLC, HNSCC, melanoma, or other limited tumor types) who have progressed on or following prior immune checkpoint inhibitor if indicated and available
• •* Part B: Participants with solid tumors who have either progressed on/after prior immune checkpoint inhibitor, or who have not received prior immune checkpoint inhibitor therapy
• •* Part C: Participants with selected tumor type who have not received systemic anticancer treatment for the tumor type (including prior immune checkpoint inhibitor
• •2. Measurable disease as defined by Lugano Classification for lymphomas or RECIST 1.1 for solid tumors
• •3. Able to provide tumor tissue(s) as defined by the protocol depending on the Part of the study at enrollment
• •4. ECOG Performance Status score 0 or 1